Merck (Schweiz) AG
Merck (Schweiz) AG is a Originators company based in Zug (Zug) recorded by Swissmedic as the authorisation holder for 31 human medicines. That places it 54 of 334 authorisation holders in Switzerland. Its portfolio is concentrated in Synthetika.
Key facts
| Sector | Originators |
|---|---|
| City | Zug |
| Canton | Zug |
| Authorisation holder | Yes |
| Medicines | 31 |
| Founded | Not available |
| Employees | 51-200 |
| Parent group | Merck KGaA |
| Activity | Not available |
| Website | merckgroup.com/ch-de |
Medicines authorised in Switzerland
Merck (Schweiz) AG is recorded by Swissmedic as the authorisation holder for 31 human medicines. The table shows 31 of them with product code and dispensing category.
Portfolio by product code
Portfolio by dispensing category
31 of 31 authorisations
| Name | Authorisation number | Dispensing category | ATC | First authorised |
|---|---|---|---|---|
| Bavencio 200 mg/10 ml | 66380 | A | L01FF04 | 2017-09-05 |
| Campral | 53090 | B | N07BB03 | 1995-08-29 |
| Cetrotide 0 | 56218 | A | H01CC02 | 2003-04-30 |
| Cetrotide 0 | 69440 | A | - | 2024-01-29 |
| Concor 5 | 47311 | B | C07AB07 | 1986-04-03 |
| Concor 5 plus | 52034 | B | C07BB07 | 1993-05-24 |
| Crinone 8 % | 53479 | B | G03DA04 | 2000-09-27 |
| Erbitux 100 mg/20 ml | 56072 | A | L01FE01 | 2003-12-01 |
| Euthyrox 25 µg | 54949 | B | H03AA01 | 1999-09-28 |
| Ezmekly 1 mg | 70387 | A | L01EE05 | 2026-04-09 |
| Ezmekly 1 mg | 70392 | A | L01EE05 | 2026-04-09 |
| Fortecortin 4 mg | 48670 | B | H02AB02 | 1988-10-18 |
| Fortecortin Inject 4 mg | 48669 | B | H02AB02 | 1990-03-28 |
| Glucophage 500 | 26061 | B | A10BA02 | 1960-03-22 |
| Gonal-f PEN 300 U.I./0.48 ml | 56689 | A | G03GA05 | 2004-04-20 |
| Lodoz 2 | 56222 | B | C07BB07 | 2003-08-05 |
| Luveris 75 IE | 55430 | A | G03GA07 | 2002-09-27 |
| Luveris 75 IE | 69516 | A | - | 2024-06-13 |
| Mavenclad 10 mg | 66831 | A | L04AA40 | 2019-03-19 |
| Novothyral | 37716 | B | H03AA03 | 1973-06-01 |
| Ogsiveo 100 mg | 70389 | A | L01XX81 | 2026-05-19 |
| Ovitrelle 250 µg | 56364 | A | G03GA08 | 2004-02-17 |
| Ovitrelle PEN | 61456 | A | - | 2011-11-14 |
| Pergoveris 150/75 | 58154 | A | - | 2008-05-13 |
| Pergoveris 150/75 | 69476 | A | - | 2024-03-28 |
| Pergoveris Pen 300 IE/150 IE/0.48 ml | 66608 | A | G03GA30 | 2018-04-13 |
| Rebif 22 (HSA-haltige Formulierung) | 54810 | B | L03AB07 | 1998-12-23 |
| Rebif 22 multidose | 60443 | B | L03AB07 | 2010-04-01 |
| Rebif 8.8 und 22 RebiDose | 62067 | B | L03AB07 | 2012-02-13 |
| Saizen Liquid 6 mg (5.83 mg/ml) | 60570 | A | H01AC01 | 2010-12-17 |
| Tepmetko 225 mg | 68113 | A | L01EP02 | 2021-06-22 |
Frequently asked questions
How many medicines does Merck (Schweiz) AG have authorised in Switzerland?
Merck (Schweiz) AG is recorded by Swissmedic as the authorisation holder for 31 human medicines (as of 1 September 2026). Different strengths under one authorisation number are not counted separately.
Where is Merck (Schweiz) AG based?
The Swiss location recorded for Merck (Schweiz) AG is Zug, Zug.
Is Merck (Schweiz) AG a Swissmedic authorisation holder?
Yes. Merck (Schweiz) AG appears in the official Swissmedic list of authorised medicinal products as an authorisation holder. Under the Therapeutic Products Act (TPA) the holder is responsible for the quality, safety and product information of its medicines in Switzerland.